Company: AEMD
Filing Date: 2025-08-13
Form Type: 10-Q
Source: 0001683168-25-006049
Chunk: 5

Company: AETHLON MEDICAL INC
Filing Date: 2025-08-13
Form: 10-Q
Item: Item 1
Chunk 5
---
 stock upon Class A and Class B warrant exercises 
     –  
     1,844,400 
  
    Tax withholding payments or tax equivalent payments for net share settlement of restricted stock units and net stock option expense 
     (5,357) 
     (5,078)
  
    Net cash (used in) provided by financing activities 
     (5,357) 
     5,379,229 

    Effect of exchange rate on changes on cash 
     (15,496) 
     (1,290)

    Net (decrease) increase in cash, cash equivalents and restricted cash 
     (1,735,790) 
     3,630,402 

    Cash, cash equivalents and restricted cash at beginning of period 
     5,599,074  
     5,529,483 

    Cash, cash equivalents and restricted cash at end of period 
    $3,863,284  
    $9,159,885 

    Supplemental disclosures of cash flow information: 

    Supplemental disclosures of non-cash investing and financing activities: 

    Par value of shares issued for vested restricted stock units and net stock option exercise 
    $13  
    $28 

    Reconciliation of cash, cash equivalents and restricted cash to the condensed consolidated balance sheets: 

    Cash and cash equivalents 
    $3,765,154  
    $9,072,379 
  
    Restricted cash 
     98,130  
     87,506 
  
    Cash, cash equivalents and restricted cash 
    $3,863,284  
    $9,159,885 

The accompanying notes are an integral part of these
condensed consolidated financial statements.

 7 

AETHLON MEDICAL, INC. AND SUBSIDIARY

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(UNAUDITED)

June 30, 2025

1. NATURE OF BUSINESS AND BASIS OF PRESENTATION ORGANIZATION

Aethlon Medical, Inc., or Aethlon, the Company, we
or us, is a medical therapeutic company focused on developing the Hemopurifier® (HP), a clinical-stage immunotherapeutic device intended
for applications in cancer, life-threatening viral infections, and organ transplantation and other areas of significant unmet needs. In
human studies (167 sessions with